Tissue Repair’s TR Pro+ wound healing gel set for wider distribution after TGA approval

Clinical-stage biopharmaceutical company Tissue Repair (ASX: TRP) has secured approval from the Therapeutic Goods Administration (TGA) for its TR Pro+ cosmeceutical topical wound-healing gel.

The approval recognises the product as an Australian listed medicine for sale in 10-gram and 50g tubes, as well as 3g sachets.

The listing will enable Tissue Repair to more broadly promote the product’s scientific and clinical data and expand its potential indications, including acute wounds and a range of dermatological conditions.

Active ingredient

TR Pro+ contains the active pharmaceutical ingredient glucoprime (0.1%) derived from yeast.

It is the core technology platform behind the company’s lead drug candidate TR987 for the treatment of venous leg ulcers and has broad applications in animal or human environments where there is a wound.

Sales of TR Pro+ recently reached a new high, with revenue for the June quarter showing growth of 130% over the previous period and Tissue Repair’s distribution network expanding to over 160 clinics.

The company said its short-term focus remains on growing the network.

Product launch

TR Pro+ was launched in June 2023 as a topical hydrogel to accelerate healing and improve skin quality after cosmetic and minor medical procedures.

TR Pro+ was part of a pilot program in New South Wales during which time it achieved monthly sales across 90 clinics.

Feedback from patients and clinicians focused on TR Pro+’s “superior” efficacy over competitor products and prompted Tissue Repair to commence exploratory discussions on potential overseas distribution agreements.

Evidence study

A real-world evidence study in 2022 saw 12 Australian dermatology clinics administer TR Pro+ over a minimum period of five days to a total of 48 enrolled patients.

The study was run independently by IQVIA Solutions Australia and patient feedback provided via an anonymous online portal showed that 71% of patients were happy with their skin recovery at day six, increasing to 81% by day 28.

Their perception of skin healing was found to have remained consistently positive across timepoints at 85% while most patients reported less itchiness and tingling when using TR Pro+ compared to other products.